Report LibraryAll Reports
Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #1
February 06, 2019This interview covers hepatocellular carcinoma (HCC) treatment trends in the US. We discuss current treatment options including the recently approved Keytruda and Lenvima. Also discussed are Phase III pipeline therapies Imfinzi and Tecentriq for the first-line setting, along with the potential of PD-1/PD-L1 therapies in the adjuvant setting.
If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).
Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.
For our disclosures, please read the Biomedtracker Research Standards.
|Indications Covered:||Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)|